Aim: Spinal cord injury (SCI) can cause severe disability. Several clinical trials of stem-cell based therapies are ongoing. We describe our experience of bone marrow mesenchymal stem cell (BMSC) therapy in a patient with complete SCI in the chronic stage. Case report: A 25-year-old man with complete SCI at T6 level presented with paraplegia for 5 years. We transplanted autologous BMSCs intramedullary. After 12 months follow-up, his Barthel index score was noticeably improved from severe to moderate dependency, and the sensation level improved from T7 to S5, but no improvement of motor function. Conclusion: Autologous BMSCs are potentially safe for patients with complete SCI in the chronic stage and may improve neurological function and quality of life.

Keywords:

Papers of special note have been highlighted as: • of interest

References

1. Dvorak MF, Noonan VK, Fallah N et al. The influence of time from injury to surgery on motor recovery and length of hospital stay in acute traumatic spinal cord injury: an observational Canadian cohort study. J. Neurotrauma 32(9), 645–654 (2015).
MedlineGoogle Scholar
2. Wilson JR, Forgione N, Fehlings MG. Emerging therapies for acute traumatic spinal cord injury. CMAJ 185(6), 485–492 (2013).
MedlineGoogle Scholar
3. Silva NA, Sousa N, Reis RL, Salgado AJ. From basics to clinical: a comprehensive review on spinal cord injury. Prog. Neurobiol. 114, 25–57 (2014).
MedlineGoogle Scholar
4. Rowland JW, Hawryluk GW, Kwon B, Fehlings MG. Current status of acute spinal cord injury pathophysiology and emerging therapies: promise on the horizon. Neurosurg. Focus. 25(5), E2 (2008).
MedlineGoogle Scholar
5. McDonald JW, Sadowsky C. Spinal-cord injury. Lancet (London, England). 359(9304), 417–425 (2002).
MedlineGoogle Scholar
6. Becker D, McDonald JW 3rd. Approaches to repairing the damaged spinal cord: overview. Handb. Clinic. Neurol. 109, 445–461 (2012).
MedlineGoogle Scholar
7. Liu D, Li X, Xiao Z et al. Different functional bio-scaffolds share similar neurological mechanism to promote locomotor recovery of canines with complete spinal cord injury. Biomaterials 214, 119230 (2019).
Medline CASGoogle Scholar
8. Fehlings MG, Hawryluk GW. Scarring after spinal cord injury. J. Neurosurg. Spine 13(2), 165–167; discussion 167–168 (2010).
MedlineGoogle Scholar
9. Bregman BS, Coumans JV, Dai HN et al. Transplants and neurotrophic factors increase regeneration and recovery of function after spinal cord injury. Prog. Brain Res. 137, 257–273 (2002).
Medline CASGoogle Scholar
10. Dasari VR, Spomar DG, Cady C, Gujrati M, Rao JS, Dinh DH. Mesenchymal stem cells from rat bone marrow downregulate caspase-3-mediated apoptotic pathway after spinal cord injury in rats. Neurochem. Res. 32(12), 2080–2093 (2007).
Medline CASGoogle Scholar
11. Emamhadi M, Soltani B, Babaei P, Mashhadinezhad H, Ghadarjani S. Influence of sexuality in functional recovery after spinal cord injury in rats. Arch. Bone Joint Surg. 4(1), 56–59 (2016).
MedlineGoogle Scholar
12. Medina RJ, Barber CL, Sabatier F et al. Endothelial progenitors: a consensus statement on nomenclature. Stem Cells Translati. Med. 6(5), 1316–1320 (2017).
MedlineGoogle Scholar
13. Ray SK, Samntaray S, Banik NL. Future directions for using estrogen receptor agonists in the treatment of acute and chronic spinal cord injury. Neur. Regen. Res. 11(9), 1418–1419 (2016).
Medline CASGoogle Scholar
14. Simcock JW, Dunn JA, Buckley NT, Mohammed KD, Beadel GP, Rothwell AG. Identification of patients with cervical SCI suitable for early nerve transfer to achieve hand opening. Spinal Cord 55(2), 131–134 (2017).
Medline CASGoogle Scholar
15. Oh SK, Jeon SR. Current concept of stem cell therapy for spinal cord injury: a review. Korean J. Neurotr. 12(2), 40–46 (2016).
Medline CASGoogle Scholar
16. Rossi F, Perale G, Papa S, Forloni G, Veglianese P. Current options for drug delivery to the spinal cord. Exp. Opin. Drug Deliv. 10(3), 385–396 (2013).
Medline CASGoogle Scholar
17. Cizkova D, Novotna I, Slovinska L et al. Repetitive intrathecal catheter delivery of bone marrow mesenchymal stromal cells improves functional recovery in a rat model of contusive spinal cord injury. J. Neurotrauma 28(9), 1951–1961 (2011).
MedlineGoogle Scholar
18. Liu WZ, Ma ZJ, Li JR, Kang XW. Mesenchymal stem cell-derived exosomes: therapeutic opportunities and challenges for spinal cord injury. Stem Cell Res. Ther. 12(1), 102 (2021). • Exosomes arising from mesenchymal stem cells provide affable functions, through intravenous injection in the rat mode, such as to inhibit A1 astrocytes, to enhance axonal regeneration, to shift macrophage to M2 subtype, and to protect the blood–spinal cord barrier.
Medline CASGoogle Scholar
19. Yousefifard M, Sarveazad A, Babahajian A et al. Growth factor gene-modified cells in spinal cord injury recovery: a systematic review. World Neurosurg. 162, 150–162.e151 (2022). • One of the major concerns is safety about that gene-modified therapy by using viral genome, which might induce genetic aberration and teratoma formation.
MedlineGoogle Scholar
20. Hou Y, Liu X, Guo Y, Liu D, Guo P, Liu J. Strategies for effective neural circuit reconstruction after spinal cord injury: use of stem cells and biomaterials. World Neurosurg. 161, 82–89 (2022). • With the improvement of 3D bioprinting technology, personalized bionic functional scaffolds can be created with accurately and efficiently complex microenvironment to restore or repair spinal cord structure.
MedlineGoogle Scholar
21. Szymoniuk M, Mazurek M, Dryla A, Kamieniak P. The application of 3D-bioprinted scaffolds for neuronal regeneration after traumatic spinal cord injury – a systematic review of preclinical in vivo studies. Exp. Neurol. 363, 114366 (2023).
Medline CASGoogle Scholar

Vol. 18, No. 12

Metrics

Downloaded 79 times

History

Received 16 June 2023

Accepted 18 September 2023

Published online 22 November 2023

Published in print December 2023

Information

Keywords

Financial disclosure

The authors have no financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Competing interests disclosure

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, stock ownership or options and expert testimony.

Writing disclosure

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained verbal and written informed consent from the patient for the inclusion of their medical and treatment history within this case report.

PDF download